Company Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function.
The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.
Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules.
It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
| Country | United States |
| Founded | 2015 |
| IPO Date | May 9, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 82 |
| CEO | Michael Richman |
Contact Details
Address: 9000 Virginia Manor Road, Suite 200 Beltsville, Maryland 20705 United States | |
| Phone | 240 399 4900 |
| Website | nextcure.com |
Stock Details
| Ticker Symbol | NXTC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001661059 |
| CUSIP Number | 65343E108 |
| ISIN Number | US65343E1082 |
| Employer ID | 47-5231247 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael S. Richman MSBA | Co-Founder, Chief Executive Officer, President and Director |
| Dr. Solomon Langermann Ph.D. | Chief Scientific Officer |
| Dr. Lieping Chen M.D., Ph.D. | Co-Founder and Chairman of Scientific Advisory Board |
| Steven P. Cobourn CPA | Chief Financial Officer |
| Dr. Timothy Mayer Ph.D. | Chief Operating Officer |
| Kevin G. Shaw | Senior Vice President and General Counsel |
| Sourav Kundu Ph.D. | Senior Vice President of Development and Manufacturing |
| Dr. Sebastien Maloveste Ph.D. | Senior Vice President of Business Development |
| Dr. Udayan Guha M.D., Ph.D. | Senior Vice President of Clinical and Translational Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | 8-K | Current Report |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Aug 1, 2024 | 10-Q | Quarterly Report |
| Aug 1, 2024 | 8-K | Current Report |
| Jun 27, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jun 21, 2024 | 8-K | Current Report |
| Jun 18, 2024 | 8-K | Current Report |